Drug-loaded self-assembled albumin nanoparticles as well as preparation method and application thereof
Through hydrogen bond-mediated self-assembly strategy, the assembly of uracilinone compounds and albumin is used to achieve the size regulation of albumin nanoparticles, solving the problem of limited scope of single-molecular albumin nanoparticles, and significantly improving the drug tumor targeting and delivery efficiency.
Patent Information
- Application Number
- CN202410929615.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the size regulation range of single-molecular albumin nanoparticles is limited, and it is impossible to achieve size regulation within a larger range, which affects its drug delivery efficiency and tumor targeting.
Using hydrogen bond-mediated self-assembly strategy, the assembly of uracilinone compound (UPy-NCO) and albumin is used to form drug-loaded self-assembled albumin nanoparticles, so that the nanoparticles size control is achieved within the range of 10 to 100 nm. Enhance tumor targeting and drug delivery capabilities.
It significantly improves the tumor-targeted distribution and anti-tumor effect of the drug, enhances the uptake of cells against anti-tumor drugs, and improves the drug release characteristics and tumor-targeting performance.
Smart Images

Figure CN118903056A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to biomedical technology, and specifically relates to a hydrogen bond-mediated anti-tumor albumin self-assembly nanoparticle, and a preparation method and application thereof. Background Art
[0002] Human serum albumin (HSA) has good biocompatibility and is used as an excellent carrier material for many nano-drug construction and anti-tumor research. In recent years, the biomimetic synthesis method using single-molecule albumin as a template has received extensive attention in the development of albumin nano-carriers and tumor-targeted drug delivery. This single-molecule albumin nanoreactor has the advantages of mild preparation conditions, good targeting, and controllable size, but its size control range is small, and the diameter under electron microscopy is generally 4 to 10 nm. Studies have shown that the size and structure of nano-carriers have an important influence on the blood circulation, tumor targeting and accumulation, intratumor penetration, cell uptake and efflux of drugs during their delivery. Therefore, the size and structure control of nano-carriers is of great significance to improving their drug delivery efficiency and enhancing anti-tumor effects.
[0003] Self-assembly strategies can be used to control the size and structure of nanocarriers. Common self-assembly driving forces include π-π interactions, hydrophobic interactions, electrostatic interactions, hydrogen bonding interactions, etc. Using hydrogen bonding interactions as the self-assembly driving force is conducive to achieving nanocarrier structure control through simple design of the donor fragment molecular structure. However, the existing hydrogen bonding interactions are weak and are not suitable for constructing nanocarriers with stable structures. Summary of the invention
[0004] In view of the prior art, the purpose of the present invention is to provide a hydrogen bond-mediated anti-tumor albumin self-assembled nanoparticle and its preparation method and application. The size of the self-assembled nanoparticles can be regulated by controlling the amount of hydrogen bond unit modification (size range 10-100 nm), which has the advantages of simple preparation process, uniform particle size, controllable size, and strong universality. As an example, the self-assembled nanoparticles loaded with doxorubicin albumin show size-dependent tumor cell inhibition, among which the self-assembled nanoparticles with a size of about 50 nm have enhanced cell inhibition compared with the single-molecule albumin nanoparticles loaded with doxorubicin before assembly, and the assembly can effectively improve the burst release of doxorubicin in the single-molecule nanoparticles before assembly, and improve the uptake of anti-tumor drugs by tumor cells; at the same time, the self-assembled nanoparticles have significantly enhanced tumor targeting, which can significantly improve the effect of tumor treatment.
[0005] The present invention adopts the following technical solutions: A drug-loaded self-assembled albumin nanoparticle is formed by assembling a drug-containing assembly unit and a hydrogen-bonding ligand; wherein the drug-containing assembly unit is a drug-loaded albumin nanoparticle; and the hydrogen-bonding ligand is a urea-pyrimidone compound.
[0006] In the present invention, the drug-loaded albumin nanoparticles are drug-loaded nanoparticles synthesized by a biomineralization method based on an albumin template; in the drug-loaded nanoparticles, the drug includes one or more of doxorubicin, oxaliplatin, silver sulfide, copper sulfide, and basic copper carbonate; and the albumin is one or more of human serum albumin, bovine serum albumin, transferrin, and ferritin.
[0007] In the present invention, the urea pyrimidone compound (UPy-NCO) is an isocyanate compound modified pyrimidine compound (UPy); wherein the pyrimidine compound has an amine group and a hydroxyl group, such as 2-amino-4-hydroxy-6-methylpyrimidine; and the isocyanate compound has a diisocyanate functional group, such as 1,6-hexamethylene diisocyanate.
[0008] In the present invention, the drug-loaded albumin nanoparticles are synthesized by biomineralization method based on human serum albumin template, and the electron microscopic size thereof is 4-10 nm; the electron microscopic size of the drug-loaded self-assembled albumin nanoparticles assembled therefrom is 10-100 nm.
[0009] The present invention discloses a method for preparing the above-mentioned drug-loaded self-assembled albumin nanoparticles, comprising the following steps: mixing drug-containing assembly primitives and hydrogen-bonding ligands to form drug-loaded self-assembled albumin nanoparticles; further, adding a hydrogen-bonding ligand solution to a drug-containing assembly primitive solution to assemble and form drug-loaded self-assembled albumin nanoparticles, wherein the solvent in the hydrogen-bonding ligand solution is an organic solvent; and the solvent in the drug-containing assembly primitive solution is water. Preferably, the mixing time is 1 to 10 hours.
[0010] The preparation method of the drug-loaded self-assembled albumin nanoparticles comprises the following steps: adding UPy organic solution to the drug-loaded biomineralized albumin nanoparticle aqueous solution according to a predetermined UPy / albumin molar ratio to induce self-assembly to form drug-loaded self-assembled albumin nanoparticles. Using drugs and albumin as raw materials, the drug-loaded biomineralized albumin nanoparticles are synthesized based on the albumin template biomineralization method; using isocyanate compounds and pyrimidine compounds (UPy) as raw materials, urea pyrimidone compounds (UPy-NCO) are prepared; the molar ratio of pyrimidine compounds (UPy) to albumin is 1:1 to 30:1.
[0011] The present invention discloses the use of the above-mentioned drug-loaded self-assembled albumin nanoparticles in the preparation of drugs for improving burst release; and also discloses its use in the preparation of anti-tumor drugs. The assembly unit of the present invention is a drug-loaded nanoparticle synthesized by a biomineralization method based on an albumin template, which has the characteristics of strong drug loading capacity, small particle size, and high biocompatibility. It can achieve precise size control of the assembly within the particle size range of 10 to 100 nm, thereby achieving effective regulation and optimization of its tumor targeting performance. Compared with the prior art, the assembly in the present invention can effectively improve the tumor targeting distribution of the drug and produce a significantly enhanced in vivo anti-tumor effect.
[0012] The hydrogen bond-mediated anti-tumor albumin self-assembled nanoparticles disclosed in the present invention include albumin (such as human serum albumin), anti-tumor drugs (such as doxorubicin) and hydrogen bond donor UPy-NCO; specifically, the assembly is composed of albumin, drugs and UPy-NCO. Taking doxorubicin-loaded albumin self-assembled nanoparticles as an example, first, doxorubicin-loaded single-molecule albumin nanoparticles are prepared by biomineralization method, and by controlling the molar ratio of UPy-NCO to albumin in the drug-loaded single-molecule albumin nanoparticles, drug-loaded self-assembled albumin nanoparticles with a size of about 10 to 120 nm (such as 15, 25, 30, 50, 80, 100 nm) are obtained respectively. The drug release behavior of the doxorubicin-loaded albumin self-assembled nanoparticles is acidic pH responsive, with sustained release within 0 to 96 h, and can greatly improve the drug leakage and burst release of doxorubicin-loaded single-molecule albumin nanoparticles in a normal pH environment before assembly; among them, the assembly with a size of about 50 nm has the strongest cytotoxic effect, IC 50 It is 1.1 μg / mL.
[0013] The present invention realizes assembly regulation of single-molecule albumin nanoparticles through surface modification of hydrogen bonding units, has good universality, can be used to construct albumin self-assembled nanoparticles loaded with doxorubicin, oxaliplatin, silver sulfide, copper sulfide, basic copper carbonate, etc., and can prepare albumin self-assembled nanoparticles with a particle size range of 10 to 100 nm and controllable size by controlling the reaction conditions.
[0014] The present invention provides a new albumin assembly strategy, which effectively solves the problem that the size control range of existing single-molecule albumin nanoreactors is only 4 to 10 nm, and the size control range cannot be controlled in a larger range. The drug-loaded self-assembled albumin nanoparticles constructed by the present invention have the characteristics of strong tumor targeting and good safety, which promotes the accumulation of drugs in tumor tissues and their entry into tumor cells, laying a foundation for the effective treatment of tumors.
[0015] The present invention provides a method for preparing the above-mentioned drug-loaded self-assembled albumin nanoparticles, comprising the following steps: (1) Dispersing 2-amino-4-hydroxy-6-methylpyrimidine in 1,6-hexamethylene diisocyanate, heating the mixture under nitrogen protection to react, thereby preparing UPy-NCO; (2) using conventional biomineralization methods to prepare drug-loaded single-molecule albumin nanoparticles (such as doxorubicin, oxaliplatin, silver sulfide, copper sulfide, basic copper carbonate, etc., as reported in previous patents or published articles); (3) Add UPy-NCO organic solvent solution to the aqueous solution of drug-loaded single-molecule albumin nanoparticles, stir and react for 1 to 10 h. After the reaction is completed, purify the sample to obtain drug-loaded self-assembled albumin nanoparticles.
[0016] The present invention provides the use of the above representative doxorubicin-loaded albumin self-assembled nanoparticles in tumor treatment or in the preparation of tumor treatment drugs.
[0017] The present invention adopts the multi-hydrogen bond donor fragment modification method for the first time and successfully prepares a variety of drug-loaded self-assembled albumin nanoparticles. The prepared self-assembled nanoparticles are evenly dispersed and the size can be adjusted in the range of 10 to 100 nm. As an example, the assembly of doxorubicin-loaded albumin self-assembled nanoparticles of about 50 nm has the strongest inhibitory effect on triple-negative breast cancer cells, IC 50 The present invention combines the quadruple hydrogen bond donor UPy-NCO with the surface amino group (-NH 2 ) Through chemical reaction to form a covalent urea group, UPy is used to modify drug-loaded single-molecule albumin nanoparticles, and self-assembled nanoparticles are formed by means of non-covalent interactions between UPy units. The present invention effectively solves the problem of limited size control range of albumin single-molecule nanoreactors; by adjusting preparation conditions such as feed ratio, the size of the assembly, drug release behavior and other physical and chemical properties are regulated to obtain drug-loaded self-assembled albumin nanoparticles with controlled drug release properties and excellent tumor targeting. Compared with single-molecule albumin nanoparticles, the self-assembled nanoparticles provided by the present invention have significant advantages in simple preparation process, controllable size within the range of 10 to 100 nm, less drug leakage, better cell uptake, stronger tumor targeting, etc., which lays the foundation for efficient tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is the mass spectrum of UPy-NCO in the synthesis example.
[0019] Figure 2 This is the H NMR spectrum of UPy-NCO in the synthesis example.
[0020] Figure 3 This is an electron micrograph of the doxorubicin-loaded single-molecule albumin nanoparticles in Example 1.
[0021] Figure 4 This is an electron microscope image of silver sulfide-loaded single-molecule albumin nanoparticles in Example 1.
[0022] Figure 5 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 2.
[0023] Figure 6 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 3.
[0024] Figure 7 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 4.
[0025] Figure 8 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 5.
[0026] Fig. 9 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 6.
[0027] Fig.10 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 7.
[0028] Fig.11 This is an electron micrograph of the doxorubicin-loaded albumin self-assembled nanoparticles in Example 8.
[0029] Fig.12 This is an electron microscope image of the silver sulfide self-assembled nanoparticles of Example 9.
[0030] Fig.13 This is an electron microscope image of the self-assembled silver sulfide nanoparticles in Example 10.
[0031] Fig.14 This is an electron microscope image of the silver sulfide self-assembled nanoparticles of Example 11.
[0032] Fig.15 This is an electron microscope image of the silver sulfide self-assembled nanoparticles of Example 12.
[0033] Fig.16 The in vitro drug release curves of the doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Example 1 and Example 7.
[0034] Fig.17 The in vitro drug release curves of the doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 5 to 8.
[0035] Fig.18 This is a graph showing the survival rate of 4T1 breast cancer cells in response to single-molecule albumin nanoparticles loaded with doxorubicin and self-assembled albumin nanoparticles loaded with doxorubicin prepared in Examples 1, 5, 6 and 7 of the present invention.
[0036] Fig.19 The results of in vivo fluorescence imaging and fluorescence quantification of doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6 and 7 of the present invention in tumor-bearing mice.
[0037] Fig. 20 The results are the tissue distribution of doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6 and 7 of the present invention in tumor-bearing mice.
[0038] Fig.21 The figure shows the tumor inhibition curves of doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5 and 7 of the present invention on a tumor-bearing mouse model (A) and a photograph of in vitro tumor tissue after the tumor inhibition experiment (B).
[0039] Fig. 22 The figure is a curve of body weight change of doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5 and 7 of the present invention in a tumor-bearing mouse model. DETAILED DESCRIPTION
[0040] Albumin nanoparticles prepared by biomimetic synthesis method with single-molecule albumin as template can enhance the efficacy of anti-tumor drugs alone, but the technical effect and drug release performance of existing albumin nanoparticles need to be improved. In the prior art, large-sized (~100 nm) drug-loaded albumin nanoparticles are mainly prepared by emulsification method, and are limited to encapsulating drugs with strong interactions with albumin, and the scope of use is limited; the preparation of albumin nanoparticles with weak interaction with albumin requires chemical cross-linking, which causes problems such as poor albumin protease degradation performance and difficulty in drug release. The present invention expands the preparation and regulation methods of drug-loaded albumin nanoparticles of different sizes through self-assembly strategy, which is of great significance for the construction of drug-loaded albumin nanomedicines based on biomineralization principles. Furthermore, the traditional emulsification method for preparing large-size albumin nanoparticles will destroy the secondary structure of the protein to a certain extent, affecting the transport and tumor targeting performance of albumin and tumor-related vascular endothelial cells related receptors, while the assembly of the present invention can retain the cell and assembly targeting ability of single-molecule or small-sized albumin nanoparticles.
[0041] The present invention has developed a nanocarrier construction strategy based on controllable albumin assembly. This assembly strategy improves the tumor cell internalization effect of the carrier and optimizes the drug encapsulation performance of the carrier by regulating the size of the carrier, thereby enhancing the tumor-targeted delivery of the albumin nanoparticles and thus improving their anti-tumor therapeutic effect. The preparation method of the drug-loaded albumin self-assembled nanoparticles of the present invention is as follows: (1) Using the biomineralization method, the drug is precipitated inside the albumin cavity to obtain a drug-loaded single-molecule albumin nanoparticle solution; (2) UPy-NCO was mixed with albumin and self-assembled to prepare drug-loaded albumin self-assembled nanoparticles.
[0042] The following is a further detailed description of the specific implementation of the present invention in conjunction with the accompanying drawings and examples. The raw materials involved are existing products, the specific preparation operations and performance tests are all conventional techniques, and the animal experiments meet the relevant requirements of Soochow University. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.
[0043] Data are presented as mean ± SD, and differences among groups were evaluated using one-way ANOVA with two-sided Student's t-test or Tukey's post hoc test. Statistical differences were defined as *P < 0.05, **P < 0.01, and ***P < 0.001.
[0044] Synthesis example 2-Amino-4-hydroxy-6-methylpyrimidine was dispersed in 1,6-hexamethylene diisocyanate and heated at 100 °C for 16 h under nitrogen protection. After the reaction, n-pentane was added, the precipitate was filtered, washed with n-pentane, and dried under reduced pressure to obtain UPy-NCO. Its mass spectrometry and nuclear magnetic hydrogen spectrum results showed that it was successfully synthesized ( Figure 1 , Figure 2 ). Embodiment 1
[0045] The preparation of assembled primitive drug-loaded single-molecule albumin nanoparticles is a conventional method, and the specific steps are as follows.
[0046] The doxorubicin-loaded single-molecule albumin nanoparticles were prepared by biomineralization. Human serum albumin (HSA) was dissolved in deionized water, and the resulting albumin solution (10 mg / mL) was incubated in a 37 °C water bath. 3.6 mg·mL -1 of ammonium sulfate aqueous solution, and then add 10 mg·mL -1 The aqueous solution of doxorubicin hydrochloride was added with NaOH solution to adjust the pH of the mixed solution to 7.5, and the mixture was stirred and reacted for 4 h in the dark. After the reaction was completed, the solution was centrifuged and purified to obtain doxorubicin-loaded single-molecule albumin nanoparticles. The prepared doxorubicin single-molecule albumin nanoparticles were photographed by electron microscopy and the hydrated particle size was measured. The results are as follows Figure 3 As shown, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of about 6.1 nm and an average hydrated particle size of 20 nm.
[0047] Silver sulfide-loaded single-molecule albumin nanoparticles were prepared by the principle of biomineralization. First, 10.0 mL of albumin solution (25 mg / mL) was incubated in a 55°C water bath, and 1.0 mL of 20.0 mM silver nitrate aqueous solution was added thereto, and the two were stirred to mix thoroughly. NaOH solution was added to the solution to adjust the pH to 12, and then 0.1 mL of 0.1 M sodium sulfide aqueous solution was added to the solution. The mixed solution was protected from light and stirred for 4 h. After the reaction was completed, the silver sulfide-loaded single-molecule albumin nanoparticles were purified. The prepared silver sulfide albumin self-assembled nanoparticles were photographed by electron microscopy, and the results are shown in Figure 2. Figure 4 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 9.6 ± 2.1 nm.
[0048] A similar method was used to prepare single-molecule albumin nanoparticles loaded with oxaliplatin, copper sulfide, and basic copper carbonate, with an average diameter of 4 to 10 nm.
[0049] The above drug-loaded albumin nanoparticles are used as drug-containing assembly units to assemble with hydrogen-bonding ligands to form assemblies. Embodiment 2
[0050] The specific steps for preparing doxorubicin-loaded albumin self-assembled nanoparticles are as follows: The protein concentration in the aqueous solution of doxorubicin-loaded single-molecule albumin (molecular weight 66.5 kDa) nanoparticles was determined using a BCA kit, and the solution was diluted to 2.0 mg mL -1 Albumin (50 mL) was added at a concentration of 1.0 mg mL -1 0.44 mL of UPy-NCO (molecular weight 293.3 Da) dimethyl sulfoxide solution was used to control the molar ratio of UPy to HSA (n UPy / n HSA ) was 1 / 1, and the reaction was stirred for 4 h. After the reaction was completed, ultrafiltration was performed to purify the self-assembled albumin nanoparticles loaded with doxorubicin. Electron microscopy was performed to obtain the self-assembled albumin nanoparticles. The results were as follows: Figure 5 As shown, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 17.6 ± 2.3 nm. Embodiment 3
[0051] The n in Example 2 UPy / n HSA Adjust to 2 / 1, i.e. add concentration of 1.0 mg mL -1 0.88 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Figure 6 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 24.3 ± 3.2 nm. Embodiment 4
[0052] The n in Example 2 UPy / n HSA Adjust to 4 / 1, i.e. add concentration of 1.0 mg mL -1 1.76 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Figure 7 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 30.6 ± 3.4 nm. Embodiment 5
[0053] The n in Example 2 UPy / n HSA Adjust to 8 / 1, i.e. add concentration of 1.0 mg mL -1 3.52 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Figure 8 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 48.0 ± 8.7 nm. Embodiment 6
[0054] The n in Example 2 UPy / n HSA Adjust to 10 / 1, i.e. add concentration of 1.0 mg mL -1 4.40 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Fig. 9 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 104.1 ± 18.7 nm. Embodiment 7
[0055] The n in Example 2 UPy / n HSA Adjust to 20 / 1, i.e. add concentration of 1.0 mg mL -1 8.80 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Fig.10 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 78.4 ± 12.8 nm. Embodiment 8
[0056] The n in Example 2 UPy / n HSA Adjust to 30 / 1, i.e. add concentration of 1.0 mg mL-1 13.20 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. Electron microscopy was performed on the prepared doxorubicin-loaded albumin self-assembled nanoparticles. The results are shown in Fig.11 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 76.1 ± 11.3 nm. Embodiment 9
[0057] The preparation of silver sulfide-loaded albumin self-assembled nanoparticles has the following specific steps: The protein concentration of the aqueous solution of silver sulfide-loaded single-molecule albumin (molecular weight 66.5 kDa) nanoparticles was determined using a BCA kit, and the solution was diluted to 2.0 mg mL -1 Albumin (50 mL), add 1.0 mg mL -1 3.52 mL of UPy-NCO (molecular weight 293.3 Da) dimethyl sulfoxide solution was added, and the molar ratio of UPy to HSA was controlled to be 8 / 1. The reaction was stirred for 4 h. After the reaction was completed, ultrafiltration was performed to purify the silver sulfide-loaded albumin self-assembled nanoparticles. The prepared silver sulfide-loaded albumin self-assembled nanoparticles were photographed by electron microscopy. The results are shown in Fig.12 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 45.0 ± 7.3 nm. Embodiment 10
[0058] According to the preparation method of Example 9, the molar ratio of UPy to HSA was controlled to be 10 / 1, that is, the concentration of UPy added was 1.0 mg / mL -1 4.40 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. The prepared silver sulfide-loaded albumin self-assembled nanoparticles were photographed by electron microscopy. The results are shown in Fig.13 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 95.2 ± 13.9 nm. Embodiment 11
[0059] According to the preparation method of Example 9, the molar ratio of UPy to HSA was controlled to be 20 / 1, that is, the concentration of UPy added was 1.0 mg / mL -1 8.80 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. The prepared silver sulfide-loaded albumin self-assembled nanoparticles were photographed by electron microscopy. The results are shown in Fig.14 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 75.0 ± 16.1 nm. Embodiment 12
[0060] According to the preparation method of Example 9, the molar ratio of UPy to HSA was controlled to be 30 / 1, that is, the concentration of UPy added was 1.0 mg / mL-1 13.20 mL of UPy-NCO dimethyl sulfoxide solution was added, and other conditions remained unchanged. The prepared silver sulfide-loaded albumin self-assembled nanoparticles were photographed by electron microscopy. The results are shown in Fig.15 As shown in the figure, the prepared nanoparticles are evenly dispersed and have uniform particle size, with an average diameter of 79.0 ± 17.8 nm. Embodiment 13
[0061] The specific steps for preparing oxaliplatin-loaded albumin self-assembled nanoparticles are as follows: The aqueous solution of oxaliplatin-loaded single-molecule albumin nanoparticles was adjusted to a protein concentration of 2.0 mg·mL -1 Albumin (50 mL), then 1.0 mg mL -1 3.52 mL of UPy-NCO (molecular weight 293.3 Da) dimethyl sulfoxide solution was added, and the molar ratio of UPy to HSA was controlled to be 8 / 1, and the reaction was stirred for 4 h. After the reaction was completed, ultrafiltration was performed to purify the oxaliplatin-loaded albumin self-assembled nanoparticles. The particle size characterization results showed that the prepared nanoparticles were evenly dispersed and uniform in particle size, with an average diameter of 47.0± 6.3 nm. Embodiment 14
[0062] The specific steps for preparing copper sulfide-loaded albumin self-assembled nanoparticles are as follows: The aqueous solution of copper sulfide-loaded single-molecule albumin nanoparticles was adjusted to a protein concentration of 2.0 mg·mL -1 Albumin (50 mL), then 1.0 mg mL -1 3.52 mL of UPy-NCO (molecular weight 293.3 Da) dimethyl sulfoxide solution was added, and the molar ratio of UPy to HSA was controlled to be 8 / 1, and the reaction was stirred for 4 h. After the reaction was completed, ultrafiltration was performed to purify the copper sulfide-loaded albumin self-assembled nanoparticles. The particle size characterization results showed that the prepared nanoparticles were evenly dispersed and uniform in particle size, with an average diameter of 46.5 ± 7.3 nm. Embodiment 15
[0063] The preparation of basic copper carbonate-loaded albumin self-assembled nanoparticles has the following specific steps: The aqueous solution of copper carbonate-loaded unimolecular albumin nanoparticles was adjusted to a protein concentration of 2.0 mg·mL -1 Albumin (50 mL), then 1.0 mg mL -13.52 mL of UPy-NCO (molecular weight 293.3 Da) dimethyl sulfoxide solution was added, and the molar ratio of UPy to HSA was controlled to be 8 / 1, and the reaction was stirred for 4 h. After the reaction was completed, ultrafiltration was performed to purify the self-assembled nanoparticles of albumin loaded with basic copper carbonate. The particle size characterization results showed that the prepared nanoparticles were evenly dispersed and uniform in particle size, with an average diameter of 48.5 ± 8.1 nm.
[0064] The performance of the doxorubicin-loaded albumin self-assembled nanoparticles prepared in the example was tested as follows: 1. The in vitro drug release behavior of the doxorubicin-loaded albumin self-assembled nanoparticles prepared in Example 1 and Example 7 was investigated by dialysis method.
[0065] (1) Evaluation of sustained release behavior of albumin self-assembled nanoparticles loaded with doxorubicin: The newly prepared self-assembled nanoparticle solution and doxorubicin single-molecule albumin nanoparticle solution were centrifuged and ultrafiltered to remove free doxorubicin. A certain amount of the ultrafiltered nanoparticle solution was dissolved in dimethyl sulfoxide, and the doxorubicin in the solution was quantified using a fluorescence spectrophotometer, and the doxorubicin in the nanoparticle solution was quantified using a fluorescence spectrophotometer. At the same time, free doxorubicin of the same concentration was prepared as a control group. 1.0 mL of each of the quantitatively quantified albumin self-assembled nanoparticle solution loaded with doxorubicin, the single-molecule albumin nanoparticle solution of doxorubicin, and the free doxorubicin solution were placed in a dialysis bag with a molecular weight cutoff of 3500 Da and sealed. A 15 mL centrifuge tube was prepared, and 10 mL of the receiving medium (acetate buffer at pH 5.0 or phosphate buffer at pH 7.4) was placed in each centrifuge tube. Three replicates were prepared in parallel. The centrifuge tubes were placed in a constant temperature oscillating box at a speed of 120 rpm and a temperature of 37°C. At different times, all the receiving medium in the centrifuge tube was removed, and 10.0 mL of buffer was added again. The content of doxorubicin in the removed receiving medium was measured using a multifunctional microplate reader, and the cumulative release percentage of doxorubicin at different time points was calculated. The results are shown in Table 1. Fig.16 As shown. Compared with the assembled element-loaded doxorubicin single-molecule albumin nanoparticles, the assembly can significantly improve the doxorubicin burst release of single-molecule albumin nanoparticles and has the characteristics of pH-responsive drug release. This feature of albumin self-assembled nanoparticles lays an important foundation for reducing drug side effects, prolonging the drug's in vivo circulation half-life, and enhancing the targeted delivery of drugs to tumors.
[0066] (2) Evaluation of the relationship between the UPy / HSA molar ratio and the sustained release behavior of self-assembled nanoparticles: The albumin self-assembled nanoparticle solutions loaded with doxorubicin prepared in Examples 5 to 8 were centrifuged to remove the precipitate, and then ultrafiltration was performed to remove the free doxorubicin. A similar method was used to measure the release of doxorubicin at different time points, and the cumulative release percentage of doxorubicin at different time points was calculated. The results are shown in FIG. Fig.17 shown.
[0067] 2. Test the cytotoxicity of the doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6, and 7.
[0068] 4T1 cells in the logarithmic growth phase were taken and 1 × 10 5 The cells were inoculated at a density of 100 / well in a 96-well cell culture plate, and 3 mL of 1640 culture medium containing 10% fetal bovine serum was added to each well, and the cells were placed in a 37°C incubator for 24 h to adhere to the cell plate wall. The dosing group was divided into 5 groups, which were the doxorubicin single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6, and 7 (particle sizes were about 6, 50, 80, and 100 nm, respectively). Different concentrations of doxorubicin were added to the cells, and the drug-containing culture medium was discarded after continuing to culture for 24 h. The CCK-8 reagent was diluted 10 times with the culture medium for use, and 100 μL of CCK-8 solution was added to each well, and the plates were placed in a 37°C incubator for incubation for 3 h. The ultraviolet absorption A450 of the plate at 450 nm was then measured using a multifunctional microplate reader. The cell viability rate can be calculated by the following formula: V = A 0 / A × 100% (V is cell viability, A is 0 The experimental results are shown in Table 1. Fig.18 As shown, the IC 50 7.7 μg·mL -1 , IC of DOX@HSA 50 4.1 μg·mL -1 , IC of DOX@ANA-50, DOX@ANA-80 and DOX@ANA-100 50 1.1 μg·mL -1 , 1.3 μg·mL -1 and 3.1 μg mL -1 .
[0069] 3. In vivo fluorescence imaging test was performed on the doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6 and 7.
[0070] (1) Establishment of mouse subcutaneous tumor model: 4T1 cells in the logarithmic growth phase were collected, centrifuged, and prepared into a cell suspension in serum-free culture medium with a concentration of 1 × 10 7 50 μL of 4T1 cell suspension was injected into the right hind leg muscle of BALB / c female mice with a syringe. When the tumor volume grew to about 200 mm 3 Experiments were conducted at the same time.
[0071] (2) Fluorescence labeling of doxorubicin-loaded albumin nanoparticles: NHS ester-activated Cy7 fluorescent probe was used to label the drug-loaded albumin nanoparticles. 4.0 mL of drug-loaded albumin nanoparticles (5.0 mg mL -1 DOX) and 1.0 mL Cy7 (0.5 mg mL -1 ) and stirred for 12 h in the dark, then dialyzed and ultrafiltered for later use.
[0072] (3) Eighteen mice bearing 4T1 tumors were divided into six groups and injected with 200 μL of free Cy7 and Cy7-labeled doxorubicin-loaded single-molecule albumin nanoparticles and self-assembled nanoparticles (with particle sizes of about 6, 50, 80, and 100 nm, respectively) prepared in Examples 1, 5, 6, and 7 through the tail vein. The injection dose was 5.0 mg kg -1 (calculated according to Cy7), the mice were scanned using a small animal in vivo imaging system at 0, 2, 6, 12, 24, and 48 h, and 35.0 mg kg -1 After all scans were completed, the images were processed by software and the fluorescence intensity of the tumor site was counted. Fig.19 shown.
[0073] 4. The doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, 6, and 7 were subjected to an in vivo tissue distribution test in mice.
[0074] (1) The above method was used to establish a tumor-bearing mouse model. Mouse models bearing 4T1 subcutaneous tumors (tumor volume ~200 mm) were obtained. 3 18 BABL / c mice were divided into 6 groups and injected with 200 μL of doxorubicin single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles (particle sizes of about 6, 50, 80, and 100 nm, respectively) prepared in Examples 1, 5, 6, and 7 through the tail vein, respectively. The injection dose was 7.5 mg·kg -1 (Calculated as DOX), 3 mice in each group. 24 hours after tail vein administration, the mice were killed by cervical dislocation, and the heart, liver, spleen, lung, kidney, and tumor of the mice were taken. Each tissue was accurately weighed and placed in a 10 mL centrifuge tube. 2.0 mL of methanol was added to each tube, and the tube was homogenized in an ice bath until there were no tissue fragments, and centrifuged for 10 min. 50 μL of the supernatant of each tissue and 50 μL of water were added to a 96-well transparent bottom black ELISA plate in a volume ratio of 1:1. The doxorubicin content in each tissue was determined using a multifunctional ELISA instrument, and the drug content of each unit mass of tissue was calculated. The results are shown in Fig. 20 shown.
[0075] 5. Investigation of the tumor inhibition effects of the doxorubicin-loaded single-molecule albumin nanoparticles and doxorubicin-loaded albumin self-assembled nanoparticles prepared in Examples 1, 5, and 7 of the present invention on the 4T1 tumor-bearing mouse model.
[0076] The 4T1 tumor-bearing mouse model was established using the above method. When the tumor volume grew to about 100 mm 3 The drugs were administered according to the following design: free doxorubicin group (dosage of doxorubicin was 5 mg / kg), PBS group, marketed doxorubicin liposome group, doxorubicin single-molecule albumin nanoparticle group prepared in Example 1 (particle size was about 6 nm), doxorubicin-loaded albumin self-assembled nanoparticle group prepared in Example 5 (particle size was about 50 nm), doxorubicin-loaded albumin self-assembled nanoparticle group prepared in Example 7 (particle size was about 80 nm), 5 mice in each group, and the drugs were administered once every 2 days. Fig.21 The volume changes of mouse tumors (A is the volume change curve, B is the actual size of the tumor) show that the tumors in the PBS group of mice grew rapidly, and the tumor volume was about 24 times the initial volume after 21 days; the free doxorubicin administration group did not produce ideal therapeutic effects due to its poor tumor targeting, and the mouse tumor volume was still about 16 times the initial volume after 21 days; the marketed doxorubicin liposomes significantly improved the anti-tumor effect compared with free doxorubicin, and the mouse tumor volume was about 11 times the initial volume after 21 days; the doxorubicin-loaded single-molecule albumin nanoparticle group prepared in Example 1 had a more significant tumor treatment effect than doxorubicin liposomes, and the mouse tumor volume was only 6 times the initial volume after 21 days; the doxorubicin-loaded albumin self-assembled nanoparticle administration group with a size of about 50 nm prepared in Example 5 showed the most significant anti-tumor effect, and the mouse tumor volume was only 3 times the initial volume after 21 days. At the same time, compared with free drugs, drug-loaded self-assembled albumin nanoparticles have better safety ( Fig. 22 ).
[0077] The present invention selects UPy (2-ureido-4[1H]-pyrimidinone, UPy), a molecule with a ureidone structure, as a donor fragment of the self-assembly driving force, which can form a strong hydrogen bond interaction through a simple head-to-tail arrangement. This donor fragment can realize the construction of a structurally stable nanocarrier, and the easily modifiable molecular structure makes its preparation process relatively simple. Therefore, the self-assembly strategy with UPy as the driving force donor fragment makes it possible to accurately control the size of albumin nanoparticles in a larger range. The drug-loaded self-assembled albumin nanoparticles prepared in the present invention can greatly improve the tumor-targeted drug delivery ability and effectively enhance the tumor inhibition effect through size and structure regulation.
Claims
1. A drug-loaded self-assembled albumin nanoparticle, characterized in that: The drug-loaded self-assembled albumin nanoparticles are assembled from drug-containing assembly primitives and hydrogen-bond ligands.
2. The drug-loaded self-assembled albumin nanoparticles according to claim 1, characterized in that: The drug-containing assembly unit is drug-loaded albumin nanoparticles; and the hydrogen-bonding ligand is a urea-pyrimidone compound.
3. The drug-loaded self-assembled albumin nanoparticles according to claim 2, characterized in that: The drug-loaded albumin nanoparticles are drug-loaded nanoparticles synthesized by a biomineralization method based on an albumin template; the urea pyrimidone compound is a pyrimidine compound modified by an isocyanate compound.
4. The drug-loaded self-assembled albumin nanoparticles according to claim 3, characterized in that: In the drug-loaded nanoparticles, the drugs include one or more of doxorubicin, oxaliplatin, silver sulfide, copper sulfide, and basic copper carbonate; the pyrimidine compound carries an amino group and a hydroxyl group; and the isocyanate compound carries a diisocyanate functional group.
5. The method for preparing the drug-loaded self-assembled albumin nanoparticles according to claim 1, characterized in that: The drug-containing assembly units and hydrogen-bonding ligands are mixed to form drug-loaded self-assembled albumin nanoparticles.
6. The method for preparing drug-loaded self-assembled albumin nanoparticles according to claim 5, characterized in that: The hydrogen-bonding ligand solution is added into the drug-containing assembly unit solution to assemble and form drug-loaded self-assembled albumin nanoparticles.
7. The method for preparing drug-loaded self-assembled albumin nanoparticles according to claim 6, characterized in that: In the hydrogen-bonding ligand solution, the solvent is an organic solvent; in the drug-containing assembly unit solution, the solvent is water.
8. Use of the drug-loaded self-assembled albumin nanoparticles according to claim 1 in the preparation of drugs for improving burst release.
9. Application of drug-containing assembly elements and hydrogen-bonding ligands in the assembly of drug-loaded self-assembled albumin nanoparticles.
10. Use of the drug-loaded self-assembled albumin nanoparticles according to claim 1 in the preparation of anti-tumor drugs.
Citation Information
Patent Citations
Doxorubicin and TRAIL co-supported albumin nanoparticle targeting preparation and preparation method thereof
CN105012271A
Antitumor platinum drug mineralization protein nanoparticles and preparation method and application thereof
CN110368374A
Copper / arsenic agent mineralized protein nanoparticles, preparation method thereof and application of copper / arsenic agent mineralized protein nanoparticles in synergistic treatment
CN115317462A
